BTIG Reiterates Buy Rating on Poseida Therapeutics, Inc (PSTX)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to BTIG Reiterates Buy Rating on Poseida Therapeutics, Inc (PSTX)

Poseida Therapeutics (PSTX) Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1

September 27, 2024 4:31 PM EDT

Poseida Therapeutics, Inc. (Nasdaq: PSTX) today announced new interim clinical data from its ongoing Phase 1 trial of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma (RRMM). Data1 demonstrated a 91% overall response rate (ORR) and compelling safety results in the 23 heavily pretreated patients in Arm C, an optimized lymphodepletion arm. The new clinical data were presented today in an oral session at the 21st International Myeloma Society (IMS) Annual Meeting in Rio de Janeiro.

P-BCMA-ALLO1 is an investigational non-viral,... More